CORRECTING and REPLACING -- uniQure Announces Results for Fourth Quarter and Financial Year 2015
04 avr. 2016 07h45 HE
|
uniQure
AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ:QURE), the tables were not included. The corrected...
uniQure Announces Results for Fourth Quarter and Financial Year 2015
04 avr. 2016 05h00 HE
|
uniQure
AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending...
uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
22 mars 2016 11h05 HE
|
uniQure
AMSTERDAM, the Netherlands, March 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its...
uniQure Announces Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial
14 mars 2016 06h00 HE
|
uniQure
AMSTERDAM, the Netherlands, March 14, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second...
uniQure to Present at the 36th Cowen & Company Health Care Conference
02 mars 2016 05h00 HE
|
uniQure
AMSTERDAM, the Netherlands, March 2, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that its management will present at the 36th Cowen &...
uniQure to Present at the RBC Capital Markets 2016 Global Healthcare Conference
15 févr. 2016 05h00 HE
|
uniQure
AMSTERDAM, the Netherlands, Feb. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at...
uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
07 janv. 2016 06h00 HE
|
uniQure
--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure's Proprietary AAV5 Vector--
--Four of Five Patients Have Fully Discontinued Prophylactic Recombinant...
uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
06 janv. 2016 16h15 HE
|
uniQure
AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its...
uniQure Appoints Dan Soland as Chief Executive Officer
18 déc. 2015 06h30 HE
|
uniQure
AMSTERDAM, the Netherlands, Dec. 18, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive...
uniQure Added to NASDAQ Biotechnology Index
14 déc. 2015 09h34 HE
|
uniQure
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology...